Tags

Type your tag names separated by a space and hit enter

Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial.
Eur Neuropsychopharmacol 2003; 13(4):267-71EN

Abstract

Patients with depression have been extensively reported to be associated with the abnormality of omega-3 polyunsaturated fatty acids (PUFAs), including significantly low eicosapentaenoic acid and docosahexaenoic acid in cell tissue contents (red blood cell membrane, plasma, etc.) and dietary intake. However, more evidence is needed to support its relation. In this study, we conducted an 8-week, double-blind, placebo-controlled trial, comparing omega-3 PUFAs (6.6 g/day) [corrected] with placebo, on the top of the usual treatment, in 28 patients with major depressive disorder. Patients in the omega-3 PUFA group had a significantly decreased score on the 21-item Hamilton Rating Scale for Depression than those in the placebo group (P < 0.001). From the preliminary findings in this study, omega-3 PUFAs could improve the short-term course of illness and were well tolerated in patients with major depressive disorder.

Authors+Show Affiliations

Department of Psychiatry, China Medical College Hospital, No. 2, Yuh-Der Road, Taichung 404, Taiwan. cobol@www.cmch.org.twNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12888186

Citation

Su, Kuan-Pin, et al. "Omega-3 Fatty Acids in Major Depressive Disorder. a Preliminary Double-blind, Placebo-controlled Trial." European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology, vol. 13, no. 4, 2003, pp. 267-71.
Su KP, Huang SY, Chiu CC, et al. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2003;13(4):267-71.
Su, K. P., Huang, S. Y., Chiu, C. C., & Shen, W. W. (2003). Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology, 13(4), pp. 267-71.
Su KP, et al. Omega-3 Fatty Acids in Major Depressive Disorder. a Preliminary Double-blind, Placebo-controlled Trial. Eur Neuropsychopharmacol. 2003;13(4):267-71. PubMed PMID: 12888186.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. AU - Su,Kuan-Pin, AU - Huang,Shih-Yi, AU - Chiu,Chih-Chiang, AU - Shen,Winston W, PY - 2003/7/31/pubmed PY - 2003/10/4/medline PY - 2003/7/31/entrez SP - 267 EP - 71 JF - European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology JO - Eur Neuropsychopharmacol VL - 13 IS - 4 N2 - Patients with depression have been extensively reported to be associated with the abnormality of omega-3 polyunsaturated fatty acids (PUFAs), including significantly low eicosapentaenoic acid and docosahexaenoic acid in cell tissue contents (red blood cell membrane, plasma, etc.) and dietary intake. However, more evidence is needed to support its relation. In this study, we conducted an 8-week, double-blind, placebo-controlled trial, comparing omega-3 PUFAs (6.6 g/day) [corrected] with placebo, on the top of the usual treatment, in 28 patients with major depressive disorder. Patients in the omega-3 PUFA group had a significantly decreased score on the 21-item Hamilton Rating Scale for Depression than those in the placebo group (P < 0.001). From the preliminary findings in this study, omega-3 PUFAs could improve the short-term course of illness and were well tolerated in patients with major depressive disorder. SN - 0924-977X UR - https://www.unboundmedicine.com/medline/citation/12888186/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924977X03000324 DB - PRIME DP - Unbound Medicine ER -